Journals / Medicine Science / 2017 / Cilt: 6 - Sayı: 2

One year follow-up cardiovascular outcomes of coraxel brand paclitaxel eluting stents: a single center experience

Pages
305–309
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

TLR, major cardiovascular event and stent thrombosis were observed more frequently in the patients using Coraxel PSS compared to those using TAXUS PSS

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coraxel (Alvimedica) stents are among those that contain paclitaxel and differ from other paclitaxel eluting stents (PES) in the amount of drug they contain.
📊
Key Findings & Data:Patients to whom stents of Coraxel brand were implanted were followed up in 1-, 3-, 6- and 12-month periods between May 2011 and August 2013 for target lesion revascularization (TLR), stent thrombosis and major cardiovascular events.
💡
Conclusion & Impact:TLR, major cardiovascular event and stent thrombosis were observed more frequently in the patients using Coraxel PSS compared to those using TAXUS PSS
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Coraxel (Alvimedica) stents are among those that contain paclitaxel and differ from other paclitaxel eluting stents (PES) in the amount of drug they contain. In this context, it is not known whether the clinical effects of Coraxel stents are different or not. In this study, the clinical effects of Coraxel stents were studied. This study was a single-centered, prospective, non-randomized real life study. Patients to whom stents of Coraxel brand were implanted were followed up in 1-, 3-, 6- and 12-month periods between May 2011 and August 2013 for target lesion revascularization (TLR), stent thrombosis and major cardiovascular events. This study enrolled a total of 78 cases. 82.1% of the cases were male. Average age was 61±11 years. Average stent length was 26.91±11.24 mm, and average stent size was 2.73±0.28 mm. 28% of the patients had TLR, 5 (6%) cases had stent thrombosis, 3 (4%) cases death from all causes, 1 (1%) case cardiac death and 55% of the cases showed major cardiovascular events. TLR, major cardiovascular event and stent thrombosis were observed more frequently in the patients using Coraxel PSS compared to those using TAXUS PSS

🔖

Cite This Article

LEVENT, F., EMREN, S. V., EREN, N. K., NAZLI, C., DUYGU, H. (2017). One year follow-up cardiovascular outcomes of coraxel brand paclitaxel eluting stents: a single center experience. Medicine Science, Cilt: 6 - Sayı: 2, 305–309. https://ajindex.com/articles/277887

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting HH, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. J Am Coll Cardiol. 2016;67(10):1235-50
  2. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5:S-6
  3. CORAXEL Paclitaxel ElutingCoronaryStentDeliverySystem http://pdf.medicalexpo.com/pdf/alvimedica/coraxel-des/77766- 75086.html access date 01.03.2016 4. Wijns W, Kolh P, Danchin N, DiMario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, SousaUva M, Taggart D. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)1; European Association for Percutaneous CardiovascularI nterventions (EAPCI). Eur Heart J. 2010;31(20):2501-55
  4. Grove E.C., Kristensen S.D.,.Stent thrombosis: definitions, mechanisms and prevention E-journal of CardiologyPractice,ESC council Volume 5 http://www.escardio.org/Journals/E-Journal-ofCardiology-Practice/Volume-5/Stent-thrombosis-definitionsmechanisms-and-prevention-Title-Stent-thrombos access date 01.03.2016 6. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver